Citius Oncology, Inc.(CTOR)Earnings, Financials & Key Ratios
CTOR•NASDAQ
Price updated Jun 19, 2026
AboutCitius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.Show more
- Revenue$0
- EBITDA-$23M-14.2%
- Net Income-$25M-17.1%
- EPS (Diluted)-0.34-13.3%
- ROE-54.42%+7.8%
CTOR Key Insights
Citius Oncology, Inc. (CTOR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CTOR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTOR Price & Volume
Citius Oncology, Inc. (CTOR) stock price & volume — 10-year historical chart
Loading chart...
CTOR Growth Metrics
Citius Oncology, Inc. (CTOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-26.51%
Return on Capital
10 Years-40.66%
5 Years-40.66%
3 Years-45.43%
Last Year-45.62%
CTOR Recent Earnings
Citius Oncology, Inc. (CTOR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (29%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.27-2600.0%
$0.01
Rev
$2M-76.2%
$7M
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.06-50.0%
$0.04
Rev
$4M-9.8%
$4M
Q4 2025
Dec 23, 2025Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.08+46.7%
$0.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.27vs $0.01-2600.0% | $2Mvs $7M-76.2% |
| Q1 2026 | Feb 13, 2026 | $0.06vs $0.04-50.0% | $4Mvs $4M-9.8% |
| Q4 2025 | Dec 23, 2025 | $0.06vs $0.06+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.08vs $0.15+46.7% | — |
Based on last 12 quarters of dataView full earnings history →
CTOR Peer Comparison
Citius Oncology, Inc. (CTOR) competitors in Clinical-stage biotech and oncology — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 |
Compare CTOR vs Peers
Citius Oncology, Inc. (CTOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTOR Income Statement
Citius Oncology, Inc. (CTOR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 5.61M |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 1.12M |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 4.49M▲ 0% |
Gross Margin % | - | - | - | - | 80.07% |
Gross Profit Growth % | - | - | - | - | - |
Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M | 48.02M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M | 41.61M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 6.86M | 4.24M | 4.92M | 6.42M | 5.83M |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 573.44K |
Operating Income | -9.71M▲ 0% | -12.12M▼ 24.8% | -20.57M▼ 69.7% | -23.52M▼ 14.3% | -43.52M▲ 0% |
Operating Margin % | - | - | - | - | -775.6% |
Operating Income Growth % | - | -24.79% | -69.72% | -14.34% | - |
EBITDA | 0 | -12.12M | -20.57M | -23.49M | -42.91M |
EBITDA Margin % | - | - | - | - | -764.74% |
EBITDA Growth % | - | - | -69.72% | -14.16% | -70.53% |
D&A (Non-Cash Add-back) | 9.71M | 0 | 0 | 0 | 573.44K |
EBIT | -9.71M | -12.12M | -20.57M | -23.49M | -43.46M |
Net Interest Income | 0 | 0 | 0 | -181.66K | -224.9K |
Interest Income | 0 | 0 | 0 | 36.37K | 72.01K |
Interest Expense | 0 | 0 | 0 | 218.03K | 296.9K |
Other Income/Expense | 0 | 0 | 0 | -181.66K | 1.57M |
Pretax Income | -9.71M▲ 0% | -12.12M▼ 24.8% | -20.57M▼ 69.7% | -23.7M▼ 15.2% | -41.95M▲ 0% |
Pretax Margin % | - | - | - | - | -747.56% |
Income Tax | 1.15M | 576K | 576K | 1.06M | 561.51K |
Effective Tax Rate % | -11.86% | -4.75% | -2.8% | -4.46% | -1.34% |
Net Income | -10.87M▲ 0% | -12.7M▼ 16.9% | -21.15M▼ 66.6% | -24.76M▼ 17.1% | -42.51M▲ 0% |
Net Margin % | - | - | - | - | -757.57% |
Net Income Growth % | - | -16.86% | -66.56% | -17.08% | -63.62% |
Net Income (Continuing) | -10.87M | -12.7M | -21.15M | -24.76M | -42.51M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.08▲ 0% | -0.19▼ 149.0% | -0.30▼ 57.9% | -0.34▼ 13.3% | -0.43▲ 0% |
EPS Growth % | - | -149.02% | -57.89% | -13.33% | -26.51% |
EPS (Basic) | -0.08 | -0.19 | -0.30 | -0.34 | - |
Diluted Shares Outstanding | 90.16M | 89.48M | 71.55M | 73.27M | 100.03M |
Basic Shares Outstanding | 90.16M | 89.48M | 71.55M | 73.27M | 100.03M |
Dividend Payout Ratio | - | - | - | - | - |
CTOR Balance Sheet
Citius Oncology, Inc. (CTOR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 2.69M | 7.73M | 10.97M | 27.54M | 29.42M |
Cash & Short-Term Investments | 0 | 0 | 112 | 3.92M | 2.63M |
Cash Only | 0 | 0 | 112 | 3.92M | 2.63M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 1.08M |
Days Sales Outstanding | - | - | - | - | 83.39 |
Inventory | 0 | 0 | 8.27M | 22.29M | 22.66M |
Days Inventory Outstanding | - | - | - | - | 6.92K |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 40M | 40M | 73.4M | 73.4M | 71.28M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 71.11M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 40M | 40M | 73.4M | 73.4M | 169.25K |
Total Assets | 42.69M▲ 0% | 47.73M▲ 11.8% | 84.37M▲ 76.7% | 100.94M▲ 19.6% | 100.7M▲ 0% |
Asset Turnover | - | - | - | - | 0.06x |
Asset Growth % | - | 11.82% | 76.74% | 19.64% | 134.71% |
Total Current Liabilities | 5.85M | 21.05M | 32.7M | 49.49M | 58.81M |
Accounts Payable | 92.31K | 1.29M | 3.71M | 13.23M | 8.88M |
Days Payables Outstanding | - | - | - | - | 3.37K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 28.4M | 22.65M | 25.87M |
Current Ratio | 0.46x | 0.37x | 0.34x | 0.56x | 0.50x |
Quick Ratio | 0.46x | 0.37x | 0.08x | 0.11x | 0.12x |
Cash Conversion Cycle | - | - | - | - | 3.64K |
Total Non-Current Liabilities | 576K | 1.15M | 5.53M | 6.59M | 6.62M |
Long-Term Debt | 0 | 0 | 3.8M | 3.8M | 3.8M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 2.82M |
Other Non-Current Liabilities | 576K | 1.15M | 1.73M | 2.78M | 0 |
Total Liabilities | 6.42M | 22.2M | 38.23M | 56.08M | 65.43M |
Total Debt | 0 | 0 | 3.8M | 3.8M | 3.8M |
Net Debt | 0 | 0 | 3.8M | -124.8K | 1.17M |
Debt / Equity | - | - | 0.08x | 0.08x | 0.11x |
Debt / EBITDA | - | - | - | - | -0.09x |
Net Debt / EBITDA | - | - | - | - | -0.03x |
Interest Coverage | - | - | - | -107.72x | -146.37x |
Total Equity | 36.27M▲ 0% | 25.54M▼ 29.6% | 46.14M▲ 80.7% | 44.87M▼ 2.8% | 35.27M▲ 0% |
Equity Growth % | - | -29.59% | 80.69% | -2.76% | 127.89% |
Book Value per Share | 0.40 | 0.29 | 0.64 | 0.61 | 0.35 |
Total Shareholders' Equity | 36.27M | 25.54M | 46.14M | 44.87M | 35.27M |
Common Stock | 6.75K | 6.75K | 7.16K | 8.35K | 9.3K |
Retained Earnings | -5.43M | -18.13M | -39.28M | -64.04M | -96.18M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
CTOR Cash Flow Statement
Citius Oncology, Inc. (CTOR) cash flow — operating, investing & free cash flow history
| Metric | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -47.97K | -601.3K | 126.35K | -5.49M | -16.86M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -1153.55% | 121.01% | -4446.59% | -614.72% |
Net Income | 380.81K | 2.42M | -21.15M | -24.76M | -42.51M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 576K | 1.06M | 573.27K |
Other Non-Cash Items | -493.02K | -3.43M | 7.5M | 8.32M | 13.74M |
Working Capital Changes | 64.24K | 411.77K | 13.2M | 9.89M | 11.34M |
Change in Receivables | 25.99K | 349.05K | 0 | 0 | -1.09M |
Change in Inventory | 0 | 0 | -2.13M | -12.65M | -6.1M |
Change in Payables | 0 | 0 | 2.42M | 9.52M | 1.25M |
Cash from Investing | -67.32M | -1.32M | -5M | -5.75M | -10.86M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | -5M | -5.75M | -10.86M |
Cash from Financing | 67.66M | 1.66M | 4.87M | 15.17M | 30.36M |
Debt Issued (Net) | 0 | 0 | 3.8M | 0 | 0 |
Equity Issued (Net) | 68.04M | 0 | 0 | 15.17M | 30.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | -383.84K | 1.66M | 1.07M | 0 | 0 |
Net Change in Cash | 289.18K▲ 0% | -256.43K▼ 188.7% | -32.63K▲ 87.3% | 3.92M▲ 12127.1% | 2.63M▲ 0% |
Free Cash Flow | -47.97K▲ 0% | -601.3K▼ 1153.5% | 126.35K▲ 121.0% | -5.49M▼ 4446.7% | -16.86M▲ 0% |
FCF Margin % | - | - | - | - | -300.41% |
FCF Growth % | - | -1153.49% | 121.01% | -4446.73% | -3243.65% |
FCF per Share | -0.00 | -0.01 | 0.00 | -0.07 | -0.17 |
FCF Conversion (FCF/Net Income) | 0.00x | 0.05x | -0.01x | 0.22x | 0.40x |
Interest Paid | 0 | 0 | 0 | 0 | 14.46K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 |
CTOR Key Ratios
Citius Oncology, Inc. (CTOR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | -41.09% | -59.01% | -54.42% | -99.47% |
Return on Invested Capital (ROIC) | -29.42% | -40.89% | -37.27% | -75.78% |
Gross Margin | - | - | - | 80.07% |
Net Margin | - | - | - | -757.57% |
Debt / Equity | - | 0.08x | 0.08x | 0.11x |
Interest Coverage | - | - | -107.72x | -146.37x |
FCF Conversion | 0.05x | -0.01x | 0.22x | 0.40x |
Related:CTOR Dividend History·CTOR Revenue History·CTOR Price History·CTOR P/E History·CTOR Financial Ratios·CTOR Institutional Holders
CTOR Frequently Asked Questions
Citius Oncology, Inc. (CTOR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Citius Oncology, Inc. (CTOR) reported $5.6M in revenue for fiscal year 2025.
Citius Oncology, Inc. (CTOR) grew revenue by 0.0% over the past year. Growth has been modest.
Citius Oncology, Inc. (CTOR) reported a net loss of $42.5M for fiscal year 2025.
Dividend & Returns
Citius Oncology, Inc. (CTOR) has a return on equity (ROE) of -54.4%. Negative ROE indicates the company is unprofitable.
Citius Oncology, Inc. (CTOR) had negative free cash flow of $16.9M in fiscal year 2025, likely due to heavy capital investments.